The Advantage of Specific Intravenous Immunoglobulin (sIVIG) on Regular IVIG: Experience of the Last Decade

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Clinical Immunology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10875-012-9842-5PMID 23229779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Small‐vessel vasculitis

  2012cited by this paper
• Autoimmune blistering diseases of the skin.

  2012cited by this paper
• Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.

  2011cited by this paper
• Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view

  2010cited by this paper
• A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs

  2010cited by this paper
• IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes.

  2010cited by this paper
• Efficacy of intravenous immunoglobulin (IVIG) affinity‐purified anti‐desmoglein anti‐idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris

  2010cited by this paper
• Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice.

  2010cited by this paper
• Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg).

  2009cited by this paper
• An ‘n‐of‐1’ placebo‐controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris

  2009cited by this paper
• Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

  2009influential reference
• Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis.

  2009cited by this paper
• Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

  2009cited by this paper
• Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis.

  2009cited by this paper
• Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

  2009cited by this paper
• Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation

  2009cited by this paper
• Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin

  2009cited by this paper
• A randomized double-blind trial of intravenous immunoglobulin for pemphigus.

  2009cited by this paper
• Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.

  2008cited by this paper
• Pemphigus Vulgaris IgG Directly Inhibit Desmoglein 3-Mediated Transinteraction1

  2008cited by this paper
• Inaugural Article: Identification of a receptor required for the anti-inflammatory activity of IVIG

  2008cited by this paper
• What is the contents of the magic draft IVIg?

  2008cited by this paper
• A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.

  2008cited by this paper
• Anti-inflammatory actions of intravenous immunoglobulin.

  2008cited by this paper
• Treatment of Myasthenia Gravis Acute Exacerbations with Intravenous Immunoglobulin

  2008cited by this paper
• Natural and disease associated anti-myeloperoxidase (MPO) autoantibodies.

  2008cited by this paper
• Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc

  2008cited by this paper
• Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy.

  2007cited by this paper
• The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.

  2007cited by this paper
• Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis.

  2007cited by this paper
• Idiotypic and anti-idiotypic elastin autoantibodies: Implications for IVIg and pregnancy loss.

  2007cited by this paper
• BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer

  2007cited by this paper
• Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

  2006cited by this paper
• Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF)

  2006cited by this paper
• Intravenous immunoglobulin in immunodeficiency states

  2005cited by this paper
• Successful Treatment of a Patient with Severe Churg-Strauss Syndrome by a Combination of Pulse Corticosteroids, Pulse Cyclophosphamide, and High-Dose Intravenous Immunoglobulin

  2005cited by this paper
• Toward molecular targeting with specific intravenous immunoglobulin preparation

  2005cited by this paper
• Immunoglobulin Replacement Therapy in Primary Antibody Deficiency Diseases – Maximizing Success

  2005cited by this paper
• Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs.

  2005cited by this paper
• Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions.

  2005cited by this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin

  2005cited by this paper
• Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome

  2004cited by this paper
• Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement.

  2004cited by this paper
• Churg-Strauss Syndrome

  2004cited by this paper
• Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan.

  2004cited by this paper
• Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin.

  2004cited by this paper
• 5th International symposium on IVIG: IVIG in the third millenium, 25-27 September 2003, Interlaken, Switzerland.

  2003cited by this paper
• Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides.

  2003cited by this paper
• Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases

  2003cited by this paper
• The antiphospholipid syndrome II : autoimmune thrombosis

  2002influential reference
• Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus.

  2002influential reference
• Induction and treatment of the antiphospholipid syndrome – lessons from animal models

  2001cited by this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

  2001cited by this paper
• Use of intravenous immunoglobulin in livedo vasculitis.

  2000cited by this paper
• Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg).

  1999cited by this paper
• Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins.

  1999cited by this paper
• Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

  1998cited by this paper
• Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway.

  1998cited by this paper
• Small-vessel vasculitis.

  1997cited by this paper
• Anti‐idiotypes against Autoantibodies in Normal Immunoglobulins: Evidence for Network Regulation of Human Autoimmune Responses

  1989cited by this paper

• Intravenous Immunoglobulin for Treatment of Patients with COVID-19: A Case-control Study

  2021cites this paper
• Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG).

  2020cites this paper
• Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning

  2020cites this paper
• IgA Triggers Cell Death of Neutrophils When Primed by Inflammatory Mediators

  2020cites this paper
• The Immune System Computes the State of the Body: Crowd Wisdom, Machine Learning, and Immune Cell Reference Repertoires Help Manage Inflammation

  2019cites this paper
• Tau-Reactive Endogenous Antibodies: Origin, Functionality, and Implications for the Pathophysiology of Alzheimer's Disease

  2019cites this paper
• Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme

  2019cites this paper
• Reconstitution of IgG Subclasses following Immunoglobulin Therapy in Adult Primary Hypogammaglobulinemia

  2018cites this paper
• Isolation of Antibodies from Human Plasma, Saliva, Breast Milk, and Gastrointestinal Fluid.

  2017cites this paper
• IVIG regulates the survival of human but not mouse neutrophils

  2017cites this paper
• Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations

  2017cites this paper
• 10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.

  2016cites this paper
• Antigen Receptor-Intrinsic Non-Self: The Key to Understanding Regulatory Lymphocyte-Mediated Idiotypic Control of Adaptive Immune Responses.

  2016cites this paper
• Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

  2015cites this paper
• On the origin of immunopathology.

  2015cites this paper
• Correction for “ Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activ

  2015cites this paper
• Anti‐citrullinated‐protein‐antibody‐specific intravenous immunoglobulin attenuates collagen‐induced arthritis in mice

  2015cites this paper
• Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study

  2014cites this paper
• Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?

  2014cites this paper
• Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute

  2014cites this paper
• Defective functions of polymorphonuclear neutrophils in patients with common variable immunodeficiency

  2014cites this paper
• Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases.

  2014cites this paper
• Anti-idiotypic antibodies

  2014cites this paper
• Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute

  2014cites this paper
• Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients

  2014cites this paper
• IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist

  2014cites this paper
• Mechanisms and potential therapeutic targets in allergic inflammation: recent insights

  2013influential citation
• Intravenous immunoglobulin and Alzheimer’s disease: what now?

  2013cites this paper
• Supporting Information File S1

  2013cites this paper
• The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis.

  2012cites this paper